Genomate Health Resources

Genomate Health Achieves Certification to ISO/IEC 27001:2022 (Information Security)

Genomate Health at AACR 2025

Genomate applied to complex HER2 positive, ER/PR positive grade III invasive carcinoma

Patient Stories

AACR: Predictivity of Genomate Validated in PDX Models

Publications

AACR: Predictivity of Genomate Validated in PDX Models

Robert Doczi, Akos Takacs, Anna Dirner, Dora Lakatos, Maria Kocsis-Steinbach, Barbara Vodicska, Dora Tihanyi, Eniko Kispeter, Reka Szalkai-Denes, William T. Beck, Petak Istvan

Case Report: JCO Precision Oncology

Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I.

Case Report: MDPI NSCLC

Urbán L, Dóczi R, Vodicska B, Kormos D, Tóth L, Takács I, Várkondi E, Tihanyi D, Lakatos D, Dirner A, Vályi-Nagy I, Peták I.

Latest Events

Genomate Health at AACR 2025

Genomate Takes the Stage at Digital Health Rewired 2025 Pitchfest

Patient Stories

See all

Genomate applied to complex HER2 positive, ER/PR positive grade III invasive carcinoma

No items found.

Latest News

Genomate Health Achieves Certification to ISO/IEC 27001:2022 (Information Security)

Revolutionizing Cancer Care: BRECISE Project Launches in Madrid to Pioneer Precision Oncology

Genomate Health’s 2024 in Review

January 15, 2025

Media Coverage

How Vietnam is Leveraging AI to Reshape Healthcare

December 1, 2024

Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 4, 2024

Webinar: Matching Patients with Treatments

The Genomate® Report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. Genomate® is a clinical decision support software and is not intended to diagnose, treat, cure, prevent, or mitigate any condition. None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Learn more.